ArticleCancer management and research2019
HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 52 citations in OpenAlex.
- Identification of lncRNAs in Breast Cancer Through Bioinformatics Analysis: Implications for Pathogenesis and Prognostic Significance.Cancer medicine · 2026Article
- Integrative analysis of HMGB3 in esophageal carcinoma: expression profile, prognostic significance, and immune microenvironment associations.Translational cancer research · 2026Article
- HMGB3: A pivotal orchestrator of therapy resistance and cancer stemness in human malignancies (Review).Oncology reports · 2026Review
- Integrative bioinformatics and molecular simulations identify HMGB3 as a key immune modulator in triple negative breast cancer.Discover oncology · 2026Article
- Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle.Frontiers in oncology · 2026Article
- Constructing an immune-related prognostic model and exploring the function of HMGB3, TNFSF4, and CORO2A in breast cancer.Translational cancer research · 2025Article
- Article
- Overview of high mobility group box 3 (HMGB3] protein.Molecular genetics and genomics : MGG · 2025Review
- Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo.Extracellular vesicles and circulating nucleic acids · 2025Review
- Structure and Functions of HMGB3 Protein.International journal of molecular sciences · 2024Review
- Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms.Heliyon · 2024Review
- CircRUNX1 drives the malignant phenotypes of lung adenocarcinoma through mediating the miR-5195-3p/HMGB3 network.General thoracic and cardiovascular surgery · 2024Article
- HMGB1/RAGE axis in tumor development: unraveling its significance.Frontiers in oncology · 2024Review
- Exosomal lncRNAs as regulators of breast cancer chemoresistance and metastasis and their potential use as biomarkers.Frontiers in oncology · 2024Review
- High-mobility group box 1 emerges as a therapeutic target for asthma.Immunity, inflammation and disease · 2023Review
- Gene Expression Profiling Reveals Potential Players of Sex Determination and Asymmetrical Development in Chicken Embryo Gonads.International journal of molecular sciences · 2023Article
- Integrated analysis of coexpression and a tumor-specific ceRNA network revealed a potential prognostic biomarker in breast cancer.Translational cancer research · 2023Article
- Molecular mechanisms of microRNA-216a during tumor progression.Cancer cell international · 2023Review
- A novel lnc-LAMC2-1:1 SNP promotes colon adenocarcinoma progression by targeting miR-216a-3p/HMGB3.Heliyon · 2022Article
- Construction and validation of a prognostic model based on 11 lymph node metastasis-related genes for overall survival in endometrial cancer.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.